Skip to main content Accessibility help
×
×
Home

An update on diet and nutritional factors in systemic lupus erythematosus management

  • Marina Aparicio-Soto (a1), Marina Sánchez-Hidalgo (a1) and Catalina Alarcón-de-la-Lastra (a1)
Abstract

Systemic lupus erythematosus (SLE) is a chronic inflammatory and autoimmune disease characterised by multiple organ involvement and a large number of complications. SLE management remains complicated owing to the biological heterogeneity between patients and the lack of safe and specific targeted therapies. There is evidence that dietary factors can contribute to the geoepidemiology of autoimmune diseases such as SLE. Thus, diet therapy could be a promising approach in SLE owing to both its potential prophylactic effects, without the side effects of classical pharmacology, and its contribution to reducing co-morbidities and improving quality of life in patients with SLE. However, the question arises as to whether nutrients could ameliorate or exacerbate SLE and how they could modulate inflammation and immune function at a molecular level. The present review summarises preclinical and clinical experiences to provide the reader with an update of the positive and negative aspects of macro- and micronutrients and other nutritional factors, including dietary phenols, on SLE, focusing on the mechanisms of action involved.

Copyright
Corresponding author
* Corresponding author: Professor Dr Catalina Alarcón-de-la-Lastra, fax +34 954 55 6074, email calarcon@us.es
References
Hide All
1. Noble, PW, Bernatsky, S, Clarke, AE, et al. (2016) DNA-damaging autoantibodies and cancer: the lupus butterfly theory. Nat Rev Rheumatol 12, 429434.
2. Tan, EM, Cohen, AS, Fries, JF, et al. (1982) The 1982 revised criteria for the classification of systemic lupus erythematosus. Arthritis Rheum 25, 12711277.
3. Crispín, JC, Liossis, SN, Kis-Toth, K, et al. (2010) Pathogenesis of human systemic lupus erythematosus: recent advances. Trends Mol Med 16, 4757.
4. Lisnevskaia, L, Murphy, G & Isenberg, D (2014) Systemic lupus erythematosus. Lancet 384, 18781888.
5. Petri, M, Orbai, AM, Alarcón, GS, et al. (2012) Derivation and validation of the Systemic Lupus International Collaborating Clinics classification criteria for systemic lupus erythematosus. Arthritis Rheum 64, 26772686.
6. Vina, ER, Utset, TO, Hannon, MJ, et al. (2014) Racial differences in treatment preferences among lupus patients: a two-site study. Clin Exp Rheumatol 32, 680688.
7. Mina, R & Brunner, HI (2013) Update on differences between childhood-onset and adult-onset systemic lupus erythematosus. Arthritis Res Ther 15, 218.
8. Borba, EF, Carvalho, JF & Bonfá, E (2006) Mechanisms of dyslipoproteinemias in systemic lupus erythematosus. Clin Dev Immunol 13, 203208.
9. Moser, KL, Kelly, JA, Lessard, CJ, et al. (2009) Recent insights into the genetic basis of systemic lupus erythematosus. Genes Immun 10, 373379.
10. Xiong, J, He, Z, Zeng, X, et al. (2014) Association of vitamin D receptor gene polymorphisms with systemic lupus erythematosus: a meta-analysis. Clin Exp Rheumatol 32, 174181.
11. Ruiz-Larrañaga, O, Migliorini, P, Uribarri, M, et al. (2016) Genetic association study of systemic lupus erythematosus and disease subphenotypes in European populations. Clin Rheumatol 35, 11611168.
12. Mirabelli, G, Cannarile, F, Bruni, C, et al. (2015) One year in review 2015: systemic lupus erythematosus. Clin Exp Rheumatol 33, 414425.
13. Cai, L, Zhang, JW, Xue, XX, et al. (2014) Meta-analysis of associations of IL1 receptor antagonist and estrogen receptor gene polymorphisms with systemic lupus erythematosus susceptibility. PLOS ONE 9, e109712.
14. Mak, A & Tay, SH (2014) Environmental factors, toxicants and systemic lupus erythematosus. Int J Mol Sci 15, 1604316056.
15. Selmi, C (2010) Autoimmunity in 2009. Autoimmun Rev 9, 795800.
16. Pan, Y, Ke, H, Yan, Z, et al. (2016) The Western-type diet induces anti-HMGB1 autoimmunity in Apoe-/- mice. Atherosclerosis 251, 3138.
17. Mu, Q, Zhang, H & Luo, XM (2015) SLE: another autoimmune disorder influenced by microbes and diet? Front Immunol 6, 608.
18. Rodríguez Huerta, MD, Trujillo-Martín, MM, Rúa-Figueroa, Í, et al. (2016) Healthy lifestyle habits for patients with systemic lupus erythematosus: a systemic review. Semin Arthritis Rheum 45, 463470.
19. Podolska, MJ, Biermann, MH, Maueröder, C, et al. (2015) Inflammatory etiopathogenesis of systemic lupus erythematosus: an update. J Inflamm Res 8, 161171.
20. Dolff, S, Bijl, M, Huitema, MG, et al. (2011) Disturbed Th1, Th2, Th17 and T(reg) balance in patients with systemic lupus erythematosus. Clin Immunol 141, 197204.
21. Chun, HY, Chung, JW, Kim, HA, et al. (2007) Cytokine IL-6 and IL-10 as biomarkers in systemic lupus erythematosus. J Clin Immunol 27, 461466.
22. Ganguly, D, Haak, S, Sisirak, V, et al. (2013) The role of dendritic cells in autoimmunity. Nat Rev Immunol 13, 566577.
23. Wu, M, Yang, J, Li, X, et al. (2016) The role of γδ T cells in systemic lupus erythematosus. J Immunol Res 2016, 2932531.
24. Nalbandian, A, Crispín, JC & Tsokos, GC (2009) Interleukin-17 and systemic lupus erythematosus: current concepts. Clin Exp Immunol 157, 209215.
25. Gaffen, SL (2008) An overview of IL-17 function and signaling. Cytokine 43, 402407.
26. Nie, J, Li, YY, Zheng, SG, et al. (2015) FOXP3+ Treg cells and gender bias in autoimmune diseases. Front Immunol 6, 493.
27. Bloch, O, Amit-Vazina, M, Yona, E, et al. (2014) Increased ERK and JNK activation and decreased ERK/JNK ratio are associated with long-term organ damage in patients with systemic lupus erythematosus. Rheumatology (Oxford) 53, 10341042.
28. Kuryłowicz, A & Nauman, J (2008) The role of nuclear factor-κB in the development of autoimmune diseases: a link between genes and environment. Acta Biochim Pol 55, 629647.
29. Kawasaki, M, Fujishiro, M, Yamaguchi, A, et al. (2011) Possible role of the JAK/STAT pathways in the regulation of T cell-interferon related genes in systemic lupus erythematosus. Lupus 20, 12311239.
30. Zhao, J, Wang, H, Huang, Y, et al. (2015) Lupus nephritis: glycogen synthase kinase 3β promotion of renal damage through activation of the NLRP3 inflammasome in lupus-prone mice. Arthritis Rheumatol 67, 10361044.
31. Telles, RW, Ferreira, GA, da Silva, NP, et al. (2010) Increased plasma myeloperoxidase levels in systemic lupus erythematosus. Rheumatol Int 30, 779784.
32. Squatrito, D, Emmi, G, Silvestri, E, et al. (2014) Pathogenesis and potential therapeutic targets in systemic lupus erythematosus: from bench to bedside. Auto Immun Highlights 5, 3345.
33. Kuhn, A, Bonsmann, G, Anders, HJ, et al. (2015) The diagnosis and treatment of systemic lupus erythematosus. Dtsch Arztebl Int 112, 423432.
34. Jordan, N & D’Cruz, D (2015) Key issues in the management of patients with systemic lupus erythematosus: latest developments and clinical implications. Ther Adv Musculoskelet Dis 7, 234246.
35. Bertsias, GK, Tektonidou, M, Amoura, Z, et al. (2012) Joint European League Against Rheumatism and European Renal Association-European Dialysis and Transplant Association (EULAR/ERA-EDTA) recommendations for the management of adult and paediatric lupus nephritis. Ann Rheum Dis 71, 17711782.
36. Buttgereit, F, Saag, KG, Cutolo, M, et al. (2005) The molecular basis for the effectiveness, toxicity, and resistance to glucocorticoids: focus on the treatment of rheumatoid arthritis. Scand J Rheumatol 34, 1421.
37. Ruiz-Irastorza, G, Danza, A & Khamashta, M (2012) Glucocorticoid use and abuse in SLE. Rheumatology (Oxford) 51, 11451153.
38. Gerstein, HC, Thorpe, KE, Taylor, DW, et al. (2002) The effectiveness of hydroxychloroquine in patients with type 2 diabetes mellitus who are refractory to sulfonylureas – a randomized trial. Diabetes Res Clin Pract 55, 209219.
39. Wallace, DJ, Metzger, AL, Stecher, VJ, et al. (1990) Cholesterol-lowering effect of hydroxychloroquine in patients with rheumatic disease: reversal of deleterious effects of steroids on lipids. Am J Med 89, 322326.
40. Borba, EF & Bonfá, E (2001) Longterm beneficial effect of chloroquine diphosphate on lipoprotein profile in lupus patients with and without steroid therapy. J Rheumatol 28, 780785.
41. Bertsias, G, Ioannidis, JP, Boletis, J, et al. (2008) EULAR recommendations for the management of systemic lupus erythematosus. Report of a Task Force of the EULAR Standing Committee for International Clinical Studies Including Therapeutics. Ann Rheum Dis 67, 195205.
42. Hahn, BH, McMahon, MA, Wilkinson, A, et al. (2012) American College of Rheumatology guidelines for screening, treatment, and management of lupus nephritis. Arthritis Care Res (Hoboken) 64, 797808.
43. Jordan, N, Lutalo, PM & D’Cruz, DP (2013) Novel therapeutic agents in clinical development for systemic lupus erythematosus. BMC Med 11, 120.
44. Hui-Yuen, JS, Reddy, A, Taylor, J, et al. (2015) Safety and efficacy of belimumab to treat systemic lupus erythematosus in academic clinical practices. J Rheumatol 42, 22882295.
45. Vilas-Boas, A, Morais, SA & Isenberg, DA (2015) Belimumab in systemic lupus erythematosus. RMD Open 1, e000011.
46. Scheinberg, MA, Hislop, CM & Martin, RS (2016) Blisibimod for treatment of systemic lupus erythematosus: with trials you become wiser. Expert Opin Biol Ther 16, 723733.
47. Stohl, W, Merrill, JT, Looney, RJ, et al. (2015) Treatment of systemic lupus erythematosus patients with the BAFF antagonist “peptibody” blisibimod (AMG 623/A-623): results from randomized, double-blind phase 1a and phase 1b trials. Arthritis Res Ther 17, 215.
48. Isenberg, DA, Petri, M, Kalunian, K, et al. (2016) Efficacy and safety of subcutaneous tabalumab in patients with systemic lupus erythematosus: results from ILLUMINATE-1, a 52-week, phase III, multicentre, randomised, double-blind, placebo-controlled study. Ann Rheum Dis 75, 323331.
49. Witcher, J, Fleischmann, R, Chindalore, VL, et al. (2016) Pharmacokinetics and safety of single doses of tabalumab in subjects with rheumatoid arthritis or systemic lupus erythematosus. Br J Clin Pharmacol 81, 908917.
50. Daikh, DI & Wofsy, D (2001) Cutting edge: reversal of murine lupus nephritis with CTLA4Ig and cyclophosphamide. J Immunol 166, 29132916.
51. Furie, R, Nicholls, K, Cheng, TT, et al. (2014) Efficacy and safety of abatacept in lupus nephritis: a twelve-month, randomized, double-blind study. Arthritis Rheumatol 66, 379389.
52. Mathian, A, Hie, M, Cohen-Aubart, F, et al. (2015) Targeting interferons in systemic lupus erythematosus: current and future prospects. Drugs 75, 835846.
53. Postal, M, Sinicato, NA, Appenzeller, S, et al. (2016) Drugs in early clinical development for systemic lupus erythematosus. Expert Opin Investig Drugs 25, 573583.
54. Greco, CM, Nakajima, C & Manzi, S (2013) Updated review of complementary and alternative medicine treatments for systemic lupus erythematosus. Curr Rheumatol Rep 15, 378.
55. Shah, M, Adams-Huet, B, Kavanaugh, A, et al. (2004) Nutrient intake and diet quality in patients with systemic lupus erythematosus on a culturally sensitive cholesterol lowering dietary program. J Rheumatol 31, 7175.
56. Bruce, IN (2005) ‘Not only...but also’: factors that contribute to accelerated atherosclerosis and premature coronary heart disease in systemic lupus erythematosus. Rheumatology (Oxford) 44, 14921502.
57. Chung, CP, Avalos, I, Oeser, A, et al. (2007) High prevalence of the metabolic syndrome in patients with systemic lupus erythematosus: association with disease characteristics and cardiovascular risk factors. Ann Rheum Dis 66, 208214.
58. Oeser, A, Chung, CP, Asanuma, Y, et al. (2005) Obesity is an independent contributor to functional capacity and inflammation in systemic lupus erythematosus. Arthritis Rheum 52, 36513659.
59. Klack, K, Bonfa, E & Borba Neto, EF (2012) Diet and nutritional aspects in systemic lupus erythematosus. Rev Bras Reumatol 52, 384408.
60. Minami, Y, Sasaki, T, Arai, Y, et al. (2003) Diet and systemic lupus erythematosus: a 4 year prospective study of Japanese patients. J Rheumatol 30, 747754.
61. Borges, MC, dos Santos, FeM, Telles, RW, et al. (2012) Nutritional status and food intake in patients with systemic lupus erythematosus. Nutrition 28, 10981103.
62. Fernandes, G, Yunis, EJ & Good, RA (1976) Influence of diet on survival of mice. Proc Natl Acad Sci U S A 73, 12791283.
63. Jolly, CA, Muthukumar, A, Avula, CP, et al. (2001) Life span is prolonged in food-restricted autoimmune-prone (NZB×NZW)F(1) mice fed a diet enriched with (n-3) fatty acids. J Nutr 131, 27532760.
64. Muthukumar, AR, Jolly, CA, Zaman, K, et al. (2000) Calorie restriction decreases proinflammatory cytokines and polymeric Ig receptor expression in the submandibular glands of autoimmune prone (NZB×NZW)F1 mice. J Clin Immunol 20, 354361.
65. Cárdeno, A, Sánchez-Hidalgo, M & Alarcón-de-la-Lastra, C (2013) An up-date of olive oil phenols in inflammation and cancer: molecular mechanisms and clinical implications. Curr Med Chem 20, 47584776.
66. Toledo, E, Hu, FB, Estruch, R, et al. (2013) Effect of the Mediterranean diet on blood pressure in the PREDIMED trial: results from a randomized controlled trial. BMC Med 11, 207.
67. Casas, R, Sacanella, E & Estruch, R (2014) The immune protective effect of the Mediterranean diet against chronic low-grade inflammatory diseases. Endocr Metab Immune Disord Drug Targets 14, 245254.
68. Miggiano, GA & Gagliardi, L (2005) Diet, nutrition and rheumatoid arthritis [article in Italian]. Clin Ter 156, 115123.
69. McKellar, G, Morrison, E, McEntegart, A, et al. (2007) A pilot study of a Mediterranean-type diet intervention in female patients with rheumatoid arthritis living in areas of social deprivation in Glasgow. Ann Rheum Dis 66, 12391243.
70. Tselios, K, Koumaras, C, Gladman, DD, et al. (2016) Dyslipidemia in systemic lupus erythematosus: just another comorbidity? Semin Arthritis Rheum 45, 604610.
71. Ardoin, SP, Sandborg, C & Schanberg, LE (2007) Management of dyslipidemia in children and adolescents with systemic lupus erythematosus. Lupus 16, 618626.
72. Borba, EF & Bonfá, E (1997) Dyslipoproteinemias in systemic lupus erythematosus: influence of disease, activity, and anticardiolipin antibodies. Lupus 6, 533539.
73. Calder, PC (2010) The 2008 ESPEN Sir David Cuthbertson Lecture: fatty acids and inflammation – from the membrane to the nucleus and from the laboratory bench to the clinic. Clin Nutr 29, 512.
74. Simopoulos, AP (2002) Omega-3 fatty acids in inflammation and autoimmune diseases. J Am Coll Nutr 21, 495505.
75. Elkan, AC, Anania, C, Gustafsson, T, et al. (2012) Diet and fatty acid pattern among patients with SLE: associations with disease activity, blood lipids and atherosclerosis. Lupus 21, 14051411.
76. Arriens, C, Hynan, LS, Lerman, RH, et al. (2015) Placebo-controlled randomized clinical trial of fish oil’s impact on fatigue, quality of life, and disease activity in systemic lupus erythematosus. Nutr J 14, 82.
77. Lozovoy, MA, Simão, AN, Morimoto, HK, et al. (2015) Fish oil n-3 fatty acids increase adiponectin and decrease leptin levels in patients with systemic lupus erythematosus. Mar Drugs 13, 10711083.
78. Wright, SA, O’Prey, FM, McHenry, MT, et al. (2008) A randomised interventional trial of omega-3-polyunsaturated fatty acids on endothelial function and disease activity in systemic lupus erythematosus. Ann Rheum Dis 67, 841848.
79. Duffy, EM, Meenagh, GK, McMillan, SA, et al. (2004) The clinical effect of dietary supplementation with omega-3 fish oils and/or copper in systemic lupus erythematosus. J Rheumatol 31, 15511556.
80. Pestka, JJ, Vines, LL, Bates, MA, et al. (2014) Comparative effects of n-3, n-6 and n-9 unsaturated fatty acid-rich diet consumption on lupus nephritis, autoantibody production and CD4+ T cell-related gene responses in the autoimmune NZBWF1 mouse. PLOS ONE 9, e100255.
81. Halade, GV, Rahman, MM, Bhattacharya, A, et al. (2010) Docosahexaenoic acid-enriched fish oil attenuates kidney disease and prolongs median and maximal life span of autoimmune lupus-prone mice. J Immunol 184, 52805286.
82. Fenton, JI, Hord, NG, Ghosh, S, et al. (2013) Immunomodulation by dietary long chain omega-3 fatty acids and the potential for adverse health outcomes. Prostaglandins Leukot Essent Fatty Acids 89, 379390.
83. Chin, S, Liu, W, Storkson, J, et al. (1992) Dietary sources of conjugated dienoic isomers of linoleic acids, a newly recognized class of anticarcinogens. J Fodd Compons Anal 5, 185197.
84. Hennessy, AA, Ross, PR, Fitzgerald, GF, et al. (2016) Sources and bioactive properties of conjugated dietary fatty acids. Lipids 51, 377397.
85. Pariza, MW, Park, Y & Cook, ME (2000) Mechanisms of action of conjugated linoleic acid: evidence and speculation. Proc Soc Exp Biol Med 223, 813.
86. Bassaganya-Riera, J, Hontecillas, R & Beitz, DC (2002) Colonic anti-inflammatory mechanisms of conjugated linoleic acid. Clin Nutr 21, 451459.
87. Bergamo, P, Luongo, D, Maurano, F, et al. (2006) Conjugated linoleic acid enhances glutathione synthesis and attenuates pathological signs in MRL/MpJ-Faslpr mice. J Lipid Res 47, 23822391.
88. Bergamo, P, Maurano, F & Rossi, M (2007) Phase 2 enzyme induction by conjugated linoleic acid improves lupus-associated oxidative stress. Free Radic Biol Med 43, 7179.
89. Yang, M & Cook, ME (2003) Dietary CLA decreased weight loss and extended survival following the onset of kidney failure in NZB/W F1 mice. Lipids 38, 2124.
90. Kritchevsky, D, Tepper, SA, Wright, S, et al. (2004) Conjugated linoleic acid isomer effects in atherosclerosis: growth and regression of lesions. Lipids 39, 611616.
91. McLeod, RS, LeBlanc, AM, Langille, MA, et al. (2004) Conjugated linoleic acids, atherosclerosis, and hepatic very-low-density lipoprotein metabolism. Am J Clin Nutr 79, 1169S1174S.
92. Yang, M, Pariza, MW & Cook, ME (2000) Dietary conjugated linoleic acid protects against end stage disease of systemic lupus erythematosus in the NZB/W F1 mouse. Immunopharmacol Immunotoxicol 22, 433449.
93. Lambert, EV, Goedecke, JH, Bluett, K, et al. (2007) Conjugated linoleic acid versus high-oleic acid sunflower oil: effects on energy metabolism, glucose tolerance, blood lipids, appetite and body composition in regularly exercising individuals. Br J Nutr 97, 10011011.
94. Tricon, S, Burdge, GC, Williams, CM, et al. (2005) The effects of conjugated linoleic acid on human health-related outcomes. Proc Nutr Soc 64, 171182.
95. Nugent, AP, Roche, HM, Noone, EJ, et al. (2005) The effects of conjugated linoleic acid supplementation on immune function in healthy volunteers. Eur J Clin Nutr 59, 742750.
96. Gaullier, JM, Halse, J, Høivik, HO, et al. (2007) Six months supplementation with conjugated linoleic acid induces regional-specific fat mass decreases in overweight and obese. Br J Nutr 97, 550560.
97. Carvalho, RF, Uehara, SK & Rosa, G (2012) Microencapsulated conjugated linoleic acid associated with hypocaloric diet reduces body fat in sedentary women with metabolic syndrome. Vasc Health Risk Manag 8, 661667.
98. Benjamin, S, Prakasan, P, Sreedharan, S, et al. (2015) Pros and cons of CLA consumption: an insight from clinical evidences. Nutr Metab (Lond) 12, 4.
99. Harbige, LS (2003) Fatty acids, the immune response, and autoimmunity: a question of n-6 essentiality and the balance between n-6 and n-3. Lipids 38, 323341.
100. Lin, BF, Jeng, SJ, Chiang, BL, et al. (1997) Dietary fat affects lipids and anti-cardiolipin antibody levels in autoimmune-prone NZB/W F1 mice. Br J Nutr 77, 657669.
101. Rosillo, M, Alcaraz, MJ, Sánchez-Hidalgo, M, et al. (2014) Anti-inflammatory and joint protective effects of extra-virgin olive-oil polyphenol extract in experimental arthritis. J Nutr Biochem 25, 12751281.
102. Rosillo, MA, Sánchez-Hidalgo, M, Sánchez-Fidalgo, S, et al. (2016) Dietary extra-virgin olive oil prevents inflammatory response and cartilage matrix degradation in murine collagen-induced arthritis. Eur J Nutr 55, 315325.
103. Aparicio-Soto, M, Sánchez-Hidalgo, M, Cárdeno, A, et al. (2016) Dietary extra virgin olive oil attenuates kidney injury in pristane-induced SLE model via activation of HO-1/Nrf-2 antioxidant pathway and suppression of JAK/STAT, NF-κB and MAPK activation. J Nutr Biochem 27, 278288.
104. Milovanov, IS, Lysenko, LV, Milovanova, LIu, et al. (2009) The role of balanced low-protein diet in inhibition of predialysis chronic kidney disease progression in patients with systemic diseases [article in Russian]. Ter Arkh 81, 5257.
105. Caetano, MC, Ortiz, TT, Terreri, MT, et al. (2009) Inadequate dietary intake of children and adolescents with juvenile idiopathic arthritis and systemic lupus erythematosus. J Pediatr (Rio J) 85, 509515.
106. Mannoor, MK, Shimabukuro, I, Tsukamotoa, M, et al. (2009) Honeybee royal jelly inhibits autoimmunity in SLE-prone NZB×NZW F1 mice. Lupus 18, 4452.
107. Huang, CY, Hsu, TC, Kuo, WW, et al. (2009) Beneficial effects of taurine on cardiac abnormality in NZB/W F1 mice fed with a high-cholesterol diet. J Agric Food Chem 57, 86358642.
108. Hsu, TC, Chiang, SY, Wu, JH, et al. (2008) Treatment with taurine attenuates hepatic apoptosis in NZB/W F1 mice fed with a high-cholesterol diet. J Agric Food Chem 56, 96859691.
109. Peters, H, Border, WA, Rückert, M, et al. (2003) l-Arginine supplementation accelerates renal fibrosis and shortens life span in experimental lupus nephritis. Kidney Int 63, 13821392.
110. Corman, LC (1985) The role of diet in animal models of systemic lupus erythematosus: possible implications for human lupus. Semin Arthritis Rheum 15, 6169.
111. Minami, Y, Hirabayashi, Y, Nagata, C, et al. (2011) Intakes of vitamin B6 and dietary fiber and clinical course of systemic lupus erythematosus: a prospective study of Japanese female patients. J Epidemiol 21, 246254.
112. Gergely, P, Niland, B, Gonchoroff, N, et al. (2002) Persistent mitochondrial hyperpolarization, increased reactive oxygen intermediate production, and cytoplasmic alkalinization characterize altered IL-10 signaling in patients with systemic lupus erythematosus. J Immunol 169, 10921101.
113. Bethunaickan, R, Sahu, R, Liu, Z, et al. (2012) Anti-tumor necrosis factor α treatment of interferon-α-induced murine lupus nephritis reduces the renal macrophage response but does not alter glomerular immune complex formation. Arthritis Rheum 64, 33993408.
114. Perl, A (2013) Oxidative stress in the pathology and treatment of systemic lupus erythematosus. Nat Rev Rheumatol 9, 674686.
115. Liao, X, Ren, J, Wei, CH, et al. (2015) Paradoxical effects of all-trans-retinoic acid on lupus-like disease in the MRL/lpr mouse model. PLOS ONE 10, e0118176.
116. Kinoshita, K, Kishimoto, K, Shimazu, H, et al. (2010) Successful treatment with retinoids in patients with lupus nephritis. Am J Kidney Dis 55, 344347.
117. Nozaki, Y, Yamagata, T, Yoo, BS, et al. (2005) The beneficial effects of treatment with all-trans-retinoic acid plus corticosteroid on autoimmune nephritis in NZB/WF mice. Clin Exp Immunol 139, 7483.
118. Handono, K, Firdausi, SN, Pratama, MZ, et al. (2016) Vitamin A improve Th17 and Treg regulation in systemic lupus erythematosus. Clin Rheumatol 35, 631638.
119. Pérez de Lema, G, Lucio-Cazaña, FJ, Molina, A, et al. (2004) Retinoic acid treatment protects MRL/lpr lupus mice from the development of glomerular disease. Kidney Int 66, 10181028.
120. Ikeda, T, Nishide, T, Ohtani, T, et al. (2005) The effects of vitamin A derivative etretinate on the skin of MRL mice. Lupus 14, 510516.
121. Petri, M, Roubenoff, R, Dallal, GE, et al. (1996) Plasma homocysteine as a risk factor for atherothrombotic events in systemic lupus erythematosus. Lancet 348, 11201124.
122. Evans, MD, Cooke, MS, Akil, M, et al. (2000) Aberrant processing of oxidative DNA damage in systemic lupus erythematosus. Biochem Biophys Res Commun 273, 894898.
123. Dusso, AS & Brown, AJ (1998) Mechanism of vitamin D action and its regulation. Am J Kidney Dis 32, S13S24.
124. Lane, NE (2010) Vitamin D and systemic lupus erythematosus: bones, muscles, and joints. Curr Rheumatol Rep 12, 259263.
125. Kamen, DL & Aranow, C (2008) The link between vitamin D deficiency and systemic lupus erythematosus. Curr Rheumatol Rep 10, 273280.
126. Borba, VZ, Vieira, JG, Kasamatsu, T, et al. (2009) Vitamin D deficiency in patients with active systemic lupus erythematosus. Osteoporos Int 20, 427433.
127. Marques, CD, Dantas, AT, Fragoso, TS, et al. (2010) The importance of vitamin D levels in autoimmune diseases. Rev Bras Reumatol 50, 6780.
128. Wahono, CS, Rusmini, H, Soelistyoningsih, D, et al. (2014) Effects of 1,25(OH)2D3 in immune response regulation of systemic lupus erithematosus (SLE) patient with hypovitamin D. Int J Clin Exp Med 7, 2231.
129. Casella, CB, Seguro, LP, Takayama, L, et al. (2012) Juvenile onset systemic lupus erythematosus: a possible role for vitamin D in disease status and bone health. Lupus 21, 13351342.
130. Caetano, M, Terreri, MT, Ortiz, T, et al. (2015) Bone mineral density reduction in adolescents with systemic erythematosus lupus: association with lack of vitamin D supplementation. Clin Rheumatol 34, 20652070.
131. Marinho, A, Carvalho, C, Boleixa, D, et al. (2016) Vitamin D supplementation, effects on FoxP3 expression in T cells and FoxP3+/IL-17A ratio and clinical course in systemic lupus erythematosus patients: a study in a Portuguese cohort. Immunol Res (epublication ahead of print version 16 July 2016).
132. Lemire, JM, Ince, A & Takashima, M (1992) 1,25-Dihydroxyvitamin D3 attenuates the expression of experimental murine lupus of MRL/l mice. Autoimmunity 12, 143148.
133. Lavi Arab, F, Rastin, M, Faraji, F, et al. (2015) Assessment of 1,25-dihydroxyvitamin D3 effects on Treg cells in a mouse model of systemic lupus erythematosus. Immunopharmacol Immunotoxicol 37, 1218.
134. Tabasi, N, Rastin, M, Mahmoudi, M, et al. (2015) Influence of vitamin D on cell cycle, apoptosis, and some apoptosis related molecules in systemic lupus erythematosus. Iran J Basic Med Sci 18, 11071111.
135. Reynolds, JA, Haque, S, Williamson, K, et al. (2016) Vitamin D improves endothelial dysfunction and restores myeloid angiogenic cell function via reduced CXCL-10 expression in systemic lupus erythematosus. Sci Rep 6, 22341.
136. Lima, GL, Paupitz, J, Aikawa, NE, et al. (2016) Vitamin D supplementation in adolescents and young adults with juvenile systemic lupus erythematosus for improvement in disease activity and fatigue scores: a randomized, double-blind, placebo-controlled trial. Arthritis Care Res (Hoboken) 68, 9198.
137. Azrielant, S & Shoenfeld, Y (2016) Eppur Si Muove: vitamin D is essential in preventing and modulating SLE. Lupus 25, 563572.
138. Kennel, KA, Drake, MT & Hurley, DL (2010) Vitamin D deficiency in adults: when to test and how to treat. Mayo Clin Proc 85, 752757; quiz 757–758.
139. Hsieh, CC & Lin, BF (2005) The effects of vitamin E supplementation on autoimmune-prone New Zealand black×New Zealand white F1 mice fed an oxidised oil diet. Br J Nutr 93, 655662.
140. Hsieh, CC & Lin, BF (2005) Opposite effects of low and high dose supplementation of vitamin E on survival of MRL/lpr mice. Nutrition 21, 940948.
141. Maeshima, E, Liang, XM, Goda, M, et al. (2007) The efficacy of vitamin E against oxidative damage and autoantibody production in systemic lupus erythematosus: a preliminary study. Clin Rheumatol 26, 401404.
142. Costenbader, KH, Kang, JH & Karlson, EW (2010) Antioxidant intake and risks of rheumatoid arthritis and systemic lupus erythematosus in women. Am J Epidemiol 172, 205216.
143. Tam, LS, Li, EK, Leung, VY, et al. (2005) Effects of vitamins C and E on oxidative stress markers and endothelial function in patients with systemic lupus erythematosus: a double blind, placebo controlled pilot study. J Rheumatol 32, 275282.
144. O’Dell, JR, McGivern, JP, Kay, HD, et al. (1988) Improved survival in murine lupus as the result of selenium supplementation. Clin Exp Immunol 73, 322327.
145. Yang, X, Yao, G, Chen, W, et al. (2015) Exacerbation of lupus nephritis by high sodium chloride related to activation of SGK1 pathway. Int Immunopharmacol 29, 568573.
146. Brown, AC (2000) Lupus erythematosus and nutrition: a review of the literature. J Ren Nutr 10, 170183.
147. D’Archivio, M, Filesi, C, Di Benedetto, R, et al. (2007) Polyphenols, dietary sources and bioavailability. Ann Ist Super Sanita 43, 348361.
148. D’Archivio, M, Santangelo, C, Scazzocchio, B, et al. (2008) Modulatory effects of polyphenols on apoptosis induction: relevance for cancer prevention. Int J Mol Sci 9, 213228.
149. Woodman, OL & Chan, ECH (2004) Vascular and anti-oxidant actions of flavonols and flavones. Clin Exp Pharmacol Physiol 31, 786790.
150. Kang, HK, Ecklund, D, Liu, M, et al. (2009) Apigenin, a non-mutagenic dietary flavonoid, suppresses lupus by inhibiting autoantigen presentation for expansion of autoreactive Th1 and Th17 cells. Arthritis Res Ther 11, R59.
151. Hsu, HC, Yang, P, Wang, J, et al. (2008) Interleukin 17-producing T helper cells and interleukin 17 orchestrate autoreactive germinal center development in autoimmune BXD2 mice. Nat Immunol 9, 166175.
152. Haas, C, Ryffel, B & Le Hir, M (1998) IFN-γ receptor deletion prevents autoantibody production and glomerulonephritis in lupus-prone (NZB×NZW)F1 mice. J Immunol 160, 37133718.
153. Guo, L, Liu, W, Lu, T, et al. (2015) Decrease of functional activated T and B cells and treatment of glomerulonephitis in lupus-prone mice using a natural flavonoid astilbin. PLOS ONE 10, e0124002.
154. Khan, N & Mukhtar, H (2013) Tea and health: studies in humans. Curr Pharm Des 19, 61416147.
155. Saito, E, Inoue, M, Sawada, N, et al. (2015) Association of green tea consumption with mortality due to all causes and major causes of death in a Japanese population: the Japan Public Health Center-based Prospective Study (JPHC Study). Ann Epidemiol 25, 512518.e513.
156. Hsu, S & Dickinson, D (2006) A new approach to managing oral manifestations of Sjogren’s syndrome and skin manifestations of lupus. J Biochem Mol Biol 39, 229239.
157. Singh, BN, Shankar, S & Srivastava, RK (2011) Green tea catechin, epigallocatechin-3-gallate (EGCG): mechanisms, perspectives and clinical applications. Biochem Pharmacol 82, 18071821.
158. Sayama, K, Oguni, I, Tsubura, A, et al. (2003) Inhibitory effects of autoimmune disease by green tea in MRL-Faslprcg/Faslprcg mice. In Vivo 17, 545552.
159. Tsai, PY, Ka, SM, Chang, JM, et al. (2011) Epigallocatechin-3-gallate prevents lupus nephritis development in mice via enhancing the Nrf2 antioxidant pathway and inhibiting NLRP3 inflammasome activation. Free Radic Biol Med 51, 744754.
160. Peairs, A, Dai, R, Gan, L, et al. (2010) Epigallocatechin-3-gallate (EGCG) attenuates inflammation in MRL/lpr mouse mesangial cells. Cell Mol Immunol 7, 123132.
161. Hsu, S, Dickinson, DP, Qin, H, et al. (2005) Inhibition of autoantigen expression by (–)-epigallocatechin-3-gallate (the major constituent of green tea) in normal human cells. J Pharmacol Exp Ther 315, 805811.
162. Fairweather, D, Frisancho-Kiss, S & Rose, NR (2008) Sex differences in autoimmune disease from a pathological perspective. Am J Pathol 173, 600609.
163. Hong, Y, Wang, T, Huang, C, et al. (2008) Soy isoflavones supplementation alleviates disease severity in autoimmune-prone MRL-lpr/lpr mice. Lupus 17, 814821.
164. Li, J & McMurray, RW (2007) Effects of estrogen receptor subtype-selective agonists on autoimmune disease in lupus-prone NZB/NZW F1 mouse model. Clin Immunol 123, 219226.
165. Zhao, JH, Sun, SJ, Horiguchi, H, et al. (2005) A soy diet accelerates renal damage in autoimmune MRL/Mp-lpr/lpr mice. Int Immunopharmacol 5, 16011610.
166. Patisaul, HB & Jefferson, W (2010) The pros and cons of phytoestrogens. Front Neuroendocrinol 31, 400419.
167. Bedell, S, Nachtigall, M & Naftolin, F (2014) The pros and cons of plant estrogens for menopause. J Steroid Biochem Mol Biol 139, 225236.
168. Schoenroth, LJ, Hart, DA, Pollard, KM, et al. (2004) The effect of the phytoestrogen coumestrol on the NZB/W F1 murine model of systemic lupus. J Autoimmun 23, 323332.
169. Hong, YH, Chao, WW, Chen, ML, et al. (2009) Ethyl acetate extracts of alfalfa (Medicago sativa L.) sprouts inhibit lipopolysaccharide-induced inflammation in vitro and in vivo. J Biomed Sci 16, 64.
170. Hong, YH, Huang, CJ, Wang, SC, et al. (2009) The ethyl acetate extract of alfalfa sprout ameliorates disease severity of autoimmune-prone MRL-lpr/lpr mice. Lupus 18, 206215.
171. Malinow, MR, Bardana, EJ, Pirofsky, B, et al. (1982) Systemic lupus erythematosus-like syndrome in monkeys fed alfalfa sprouts: role of a nonprotein amino acid. Science 216, 415417.
172. Roberts, JL & Hayashi, JA (1983) Exacerbation of SLE associated with alfalfa ingestion. N Engl J Med 308, 1361.
173. Imran, M, Ahmad, N, Anjum, FM, et al. (2015) Potential protective properties of flax lignan secoisolariciresinol diglucoside. Nutr J 14, 71.
174. Hall, AV, Parbtani, A, Clark, WF, et al. (1993) Abrogation of MRL/lpr lupus nephritis by dietary flaxseed. Am J Kidney Dis 22, 326332.
175. Clark, WF, Muir, AD, Westcott, ND, et al. (2000) A novel treatment for lupus nephritis: lignan precursor derived from flax. Lupus 9, 429436.
176. Clark, WF, Parbtani, A, Huff, MW, et al. (1995) Flaxseed: a potential treatment for lupus nephritis. Kidney Int 48, 475480.
177. Clark, WF, Kortas, C, Heidenheim, AP, et al. (2001) Flaxseed in lupus nephritis: a two-year nonplacebo-controlled crossover study. J Am Coll Nutr 20, 143148.
178. Handono, K, Pratama, MZ, Endharti, AT, et al. (2015) Treatment of low doses curcumin could modulate Th17/Treg balance specifically on CD4+ T cell cultures of systemic lupus erythematosus patients. Cent Eur J Immunol 40, 461469.
179. Kurien, BT, Harris, VM, Quadri, SM, et al. (2015) Significantly reduced lymphadenopathy, salivary gland infiltrates and proteinuria in MRL-lpr/lpr mice treated with ultrasoluble curcumin/turmeric: increased survival with curcumin treatment. Lupus Sci Med 2, e000114.
180. Lee, H, Kim, H, Lee, G, et al. (2013) Curcumin attenuates lupus nephritis upon interaction with regulatory T cells in New Zealand black/white mice. Br J Nutr 110, 6976.
181. Khajehdehi, P, Zanjaninejad, B, Aflaki, E, et al. (2012) Oral supplementation of turmeric decreases proteinuria, hematuria, and systolic blood pressure in patients suffering from relapsing or refractory lupus nephritis: a randomized and placebo-controlled study. J Ren Nutr 22, 5057.
182. Foxley, S, Zamora, M, Hack, B, et al. (2013) Curcumin aggravates CNS pathology in experimental systemic lupus erythematosus. Brain Res 1504, 8596.
183. Nakata, R, Takahashi, S & Inoue, H (2012) Recent advances in the study on resveratrol. Biol Pharm Bull 35, 273279.
184. Wang, ZL, Luo, XF, Li, MT, et al. (2014) Resveratrol possesses protective effects in a pristane-induced lupus mouse model. PLOS ONE 9, e114792.
185. Auborn, KJ, Qi, M, Yan, XJ, et al. (2003) Lifespan is prolonged in autoimmune-prone (NZB/NZW) F1 mice fed a diet supplemented with indole-3-carbinol. J Nutr 133, 36103613.
186. Yan, XJ, Qi, M, Telusma, G, et al. (2009) Indole-3-carbinol improves survival in lupus-prone mice by inducing tandem B- and T-cell differentiation blockades. Clin Immunol 131, 481494.
187. McAlindon, TE, Gulin, J, Chen, T, et al. (2001) Indole-3-carbinol in women with SLE: effect on estrogen metabolism and disease activity. Lupus 10, 779783.
188. Peuhkuri, K, Sihvola, N & Korpela, R (2012) Dietary factors and fluctuating levels of melatonin. Food Nutr Res 56, 10.3402/fnr.v56i0.17252.
189. Sae-Teaw, M, Johns, J, Johns, NP, et al. (2013) Serum melatonin levels and antioxidant capacities after consumption of pineapple, orange, or banana by healthy male volunteers. J Pineal Res 55, 5864.
190. Robeva, R, Tanev, D, Kirilov, G, et al. (2013) Decreased daily melatonin levels in women with systemic lupus erythematosus – a short report. Balkan Med J 30, 273276.
191. Jimenez-Caliani, AJ, Jimenez-Jorge, S, Molinero, P, et al. (2006) Sex-dependent effect of melatonin on systemic erythematosus lupus developed in Mrl/Mpj-Faslpr mice: it ameliorates the disease course in females, whereas it exacerbates it in males. Endocrinology 147, 17171724.
192. Jimenez-Caliani, AJ, Jimenez-Jorge, S, Molinero, P, et al. (2008) Treatment with testosterone or estradiol in melatonin treated females and males MRL/MpJ-Faslpr mice induces negative effects in developing systemic lupus erythematosus. J Pineal Res 45, 204211.
193. Zhou, LL, Wei, W, Si, JF, et al. (2010) Regulatory effect of melatonin on cytokine disturbances in the pristane-induced lupus mice. Mediators Inflamm 2010, 951210.
194. Medrano-Campillo, P, Sarmiento-Soto, H, Álvarez-Sánchez, N, et al. (2015) Evaluation of the immunomodulatory effect of melatonin on the T-cell response in peripheral blood from systemic lupus erythematosus patients. J Pineal Res 58, 219226.
195. Clark, WF & Parbtani, A (1994) Omega-3 fatty acid supplementation in clinical and experimental lupus nephritis. Am J Kidney Dis 23, 644647.
196. Walton, AJ, Snaith, ML, Locniskar, M, et al. (1991) Dietary fish oil and the severity of symptoms in patients with systemic lupus erythematosus. Ann Rheum Dis 50, 463466.
197. Kim, YJ, Yokozawa, T & Chung, HY (2005) Effects of energy restriction and fish oil supplementation on renal guanidino levels and antioxidant defences in aged lupus-prone B/W mice. Br J Nutr 93, 835844.
198. Muthukumar, A, Zaman, K, Lawrence, R, et al. (2003) Food restriction and fish oil suppress atherogenic risk factors in lupus-prone (NZB×NZW) F1 mice. J Clin Immunol 23, 2333.
199. Bhattacharya, A, Lawrence, RA, Krishnan, A, et al. (2003) Effect of dietary n-3 and n-6 oils with and without food restriction on activity of antioxidant enzymes and lipid peroxidation in livers of cyclophosphamide treated autoimmune-prone NZB/W female mice. J Am Coll Nutr 22, 388399.
200. Chang, SC, Chiang, BL, Wu, WM, et al. (1999) Different dietary fats influence serum and tissue lipids and anti-cardiolipin antibody levels in autoimmune-prone NZB/W F1 mice. Br J Nutr 81, 331340.
201. Chandrasekar, B, Troyer, DA, Venkatraman, JT, et al. (1995) Dietary omega-3 lipids delay the onset and progression of autoimmune lupus nephritis by inhibiting transforming growth factor β mRNA and protein expression. J Autoimmun 8, 381393.
202. Chandrasekar, B & Fernandes, G (1994) Decreased pro-inflammatory cytokines and increased antioxidant enzyme gene expression by omega-3 lipids in murine lupus nephritis. Biochem Biophys Res Commun 200, 893898.
203. Robinson, DR, Prickett, JD, Polisson, R, et al. (1985) The protective effect of dietary fish oil on murine lupus. Prostaglandins 30, 5175.
204. Venkatraman, JT & Chu, WC (1999) Effects of dietary ω3 and ω6 lipids and vitamin E on proliferative response, lymphoid cell subsets, production of cytokines by spleen cells, and splenic protein levels for cytokines and oncogenes in MRL/MpJ-lpr/lpr mice. J Nutr Biochem 10, 582597.
205. Spurney, RF, Ruiz, P, Albrightson, CR, et al. (1994) Fish oil feeding modulates leukotriene production in murine lupus nephritis. Prostaglandins 48, 331348.
206. Robinson, DR, Prickett, JD, Makoul, GT, et al. (1986) Dietary fish oil reduces progression of established renal disease in (NZB×NZW)F1 mice and delays renal disease in BXSB and MRL/1 strains. Arthritis Rheum 29, 539546.
207. Halade, GV, Williams, PJ, Veigas, JM, et al. (2013) Concentrated fish oil (Lovaza®) extends lifespan and attenuates kidney disease in lupus-prone short-lived (NZB×NZW)F1 mice. Exp Biol Med (Maywood) 238, 610622.
208. Godfrey, DG, Stimson, WH, Watson, J, et al. (1986) Effects of dietary supplementation on autoimmunity in the MRL/lpr mouse: a preliminary investigation. Ann Rheum Dis 45, 10191024.
209. Handono, K, Sidarta, YO, Pradana, BA, et al. (2014) Vitamin D prevents endothelial damage induced by increased neutrophil extracellular traps formation in patients with systemic lupus erythematosus. Acta Med Indones 46, 189198.
210. Ben-Zvi, I, Aranow, C, Mackay, M, et al. (2010) The impact of vitamin D on dendritic cell function in patients with systemic lupus erythematosus. PLoS ONE 5, e9193.
211. Weimann, BJ & Hermann, D (1999) Inhibition of autoimmune deterioration in MRL/lpr mice by vitamin E. Int J Vitam Nutr Res 69, 255261.
Recommend this journal

Email your librarian or administrator to recommend adding this journal to your organisation's collection.

Nutrition Research Reviews
  • ISSN: 0954-4224
  • EISSN: 1475-2700
  • URL: /core/journals/nutrition-research-reviews
Please enter your name
Please enter a valid email address
Who would you like to send this to? *
×

Keywords

Metrics

Altmetric attention score

Full text views

Total number of HTML views: 0
Total number of PDF views: 0 *
Loading metrics...

Abstract views

Total abstract views: 0 *
Loading metrics...

* Views captured on Cambridge Core between <date>. This data will be updated every 24 hours.

Usage data cannot currently be displayed